All In Biotech

Drug Trial Radar · NCT05384977

Mass Balance Study of NV-5138 in Healthy Male Subjects

An Open-label, Single Dose, Mass Balance Study to Assess the Disposition of [14C]-NV-5138 in Healthy Male Subjects

Last checked: Nov 19, 2026Latest source record: May 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

6

Actual

Start

Nov 11, 2021

Primary completion

Dec 9, 2021

Study completion Dec 9, 2021

Sponsor

Lead sponsor
Supernus Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
May 23, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 40 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of this study is to assess the mass balance and routes of excretion of total radioactivity after a single oral dose of 1600 mg \[14C\]-NV-5138.

Conditions

  • Healthy Volunteers

Interventions

  • [14C]-NV-5138Drug

    Single dose, given as oral solution, 1600 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative total radioactivity in urine and faecesTime frame: urine and fecal samples up to 168 hours post dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Quotient Sciences

    Ruddington, Nottingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.